Serina Therapeutics

SERPhase 1

Founded 1967serinatherapeutics.com

Serina Therapeutics is focused on transforming drug delivery through its innovative POZylation technology, which attaches a proprietary polymer to existing drugs to improve their performance. The company's strategy centers on applying this platform to well-characterized molecules, like apomorphine for Parkinson's, to create enhanced therapies with reduced dosing frequency and side effects. By leveraging the 505(b)(2) pathway and device partnerships, Serina aims to accelerate time to market. Its lead program, SER-252, exemplifies this approach by offering a potential best-in-class, long-acting injectable for advanced Parkinson's patients.

Market Cap

$27.4M

Founded

1967

Focus

Drug DeliverySmall Molecules

AI Company Overview

Technology Platform

The POZ Platform™ is a proprietary polymer conjugation technology that attaches a specific polymer to drug molecules to enable precise, controlled, and sustained release, improving pharmacokinetics and allowing for less frequent dosing via subcutaneous or intramuscular injection.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
SER-214	Parkinson's Disease	Phase 1
SER-252 (PEOZ-apomorphine)	PARKINSON DISEASE (Disorder)	Phase 1

Funding History

Total raised: $50M

IPO$25MUndisclosedOct 15, 2023

Series A$20MUndisclosedMar 15, 2021

Seed$5MUndisclosedJun 15, 2018

Opportunities

The primary opportunity is to disrupt the advanced Parkinson's treatment paradigm by replacing complex infusion pumps with a simple, twice-weekly injection.

Success with SER-252 would validate the POZ Platform, creating a pipeline-in-a-box opportunity to develop enhanced versions of other proven drugs across neurology, oncology, and chronic diseases, leveraging the faster 505(b)(2) regulatory pathway.

Risk Factors

Key risks include clinical trial failure for SER-252, unforeseen safety issues with the POZ polymer technology, regulatory challenges despite the 505(b)(2) pathway, competition from existing and new Parkinson's therapies, and the company's dependence on raising additional capital to fund development as a pre-revenue entity.

Competitive Landscape

In Parkinson's, Serina competes directly with existing apomorphine injections and infusion pumps, differentiating on extreme dosing convenience (twice-weekly vs. continuous). Broader competition comes from other drug delivery technology companies. Serina's strategic edge is its focus on optimizing proven molecules for faster development, rather than discovering novel drugs.